Drugs / Decetabine
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06109064 Background | Oct 2023 → Feb 2024 | myelodysplastic syndrome | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06105658 Background | Oct 2023 → Feb 2024 | acute myeloid leukemia | Anhui Provincial Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decetabine | “Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)” NCT06105658 ↗ |